Amide-based inhibitors of p38α MAP kinase. Part 2: Design, synthesis and SAR of potent N-pyrimidyl amides

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 8, 2010, Pages 2560-2563

  Tester, Richland ^a   Tan, Xuefei ^a   Luedtke, Gregory R ^a   Nashashibi, Imad ^a   Schinzel, Kurt ^a   Liang, Weiling ^a   Jung, Joon ^a   Dugar, Sundeep ^a   Liclican, Albert ^a   Tabora, Jocelyn ^a   Levy, Daniel E ^a   Do, Steven ^a  

^a SCIOS INC   (United States)

Author keywords

Antiinflammatory; Kinase; MAP; p38

Indexed keywords

AMIDE; AMINE; BENZYL DERIVATIVE; CYTOCHROME P450 3A4; FURAN DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PYRIMIDINE DERIVATIVE;

ARTICLE; CHEMICAL MODIFICATION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR INTERACTION; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

AMIDES; DRUG DESIGN; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950045753     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.02.090     Document Type: Article

References (27)

1. Han J., Lee J.-D., Bibbs S.L., and Ulevitch R.J. Science 265 (1994) 808
2. Lee J.C., Kassis S., Kumar S., Badger A., and Adams J.L. Pharmacol. Ther. 82 (1999) 389
3. Foster M.L., Halley F., and Souness J.E. Drug News Perspect. 13 (2000) 488
4. Pargellis C., and Regan J. Curr. Opin. Invest. Drugs 4 (2003) 566
5. Smith R.J. Drug Discovery Today 10 (2005) 1598
6. Badger A.M., Bradbeer J.N., Votta B., Lee J.C., Adams J.L., and Griswold D.E. J. Pharmacol. Exp. Ther. 279 (1996) 1453
7. Kubota T., Miyagishima M., Alvarez R.J., Kormos R., Rosenblum W.D., Demetris A.J., Semigran M.J., Dec G.W., Holubkov R., McTiernan C.F., Mann D.L., Feldman A.M., and McNamara D.M. J. Heart Lung Transplant. 19 (2000) 819
8. Sticherling M. Drug Discovery Today: Dis. Mech. 2 (2005) 275
9. Herlaar E., and Brown Z. Mol. Med. Today 5 (1999) 439
10. Lee J.C., Kumar S., Griswold D.E., Underwood D.C., Votta B.J., and Adams J.L. Immunopharmacology 47 (2000) 185
11. Kumar S., Boehm J., and Lee J.C. Nat. Rev. Drug Disc. 2 (2003) 717
12. Saklatvala J. Curr. Opin. Pharmacol. 4 (2004) 372-377
13. Ashwell J.D. Nat. Rev. Immunol. 33 (2006) 1447
14. Diller D.J., Lin T.H., and Metzger A. Curr. Top. Med. Chem. 5 (2005) 953
15. Hynes Jr. J., and Leftheris K. Curr. Top. Med. Chem. 5 (2005) 967
16. Goldstein D.M., and Gabriel T. Curr. Top. Med. Chem. 5 (2005) 1017
17. Dominguez C., Powers D.A., and Tamayo N. Curr. Opin. Drug Discov. Devel. 4 (2005) 421
18. Wagner G., and Laufer S. Med. Res. Rev. 26 (2006) 1
19. Luedtke, G. R.; Schinzel, K.; Tan, X.; Tester, R. W.; Nashashibi, I.; Xu, Y.-j.; Dugar, S.; Levy, D. E.; Jung, J. Bioorg. Med. Chem. Lett. doi:10.1016/j.bmcl.2010.02.088.
20. Docking studies were conducted using a high-resolution p38α X-ray structure of p38α (PDB ID: 1ove). The extra-precision mode of Glide, a ligand-receptor docking tool from Schrodinger, LLC, was used to generate a number of poses for analogs 3, 8e, and 8l, which were further filtered by visual inspection.
21. Mavunkel B.J., Perumattam J.J., Tan X., Luedtke G.R., Lu Q., Lim D., Kizer D., Dugar S., Chakravarty S., Xu Y.-j., Jung J., Liclican A., Levy D.E., and Tabora J. Bioorg. Med. Chem. Lett. 20 (2010) 1059
22. The LPS/TNFα Human Whole Blood Assay was run as described in Mavunkel, B.; Dugar, S.; Luedtke, G.; Tan, X.; McEnroe, G. U.S. patent 6,696,443, 2004.
23. Davies S.P., Reddy H., Caivano M., and Cohen P. Biochem. J. 351 (2000) 95
24. Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., Abdel-Meguid S., Adams J.L., and Goldsmith E.J. Structure 6 (1998) 1117
25. Lisnock J., Tebben A., Frantz B., O'Neill E.A., Croft G., O'Keefe S.J., Li B., Hacker C., De Laszlo S., Smith A., Libby B., Liverton N., Hermes J., and LoGrasso P. Biochemistry 37 (1998) 16573
26. Tester, R.; Tan, X.; Schinzel, K.; Nashashibi, I.; Luedtke, G. R.; Liang, W.; Jung, J.; Goehring, R. R.; Dugar, S.; Do, S. US 2006/199821, 2006.
27. 5 Supersomes™, 50 mM 7-benzyloxy-4-(trifluoromethyl)-coumarin, 0.5 M potassium phosphate) was dispensed to columns 1 through 11. The liquid was dispensed in a stream to facilitate mixing. The lid was replaced and incubation continued at 37 °C for 30 min. With a miltichannel pipette, 0.075 mL of STOP solution (80% acetonitrile/20% 0.5 M tris base) was dispensed to all wells. Dispense the liquid in a stream to facilitate mixing. The enzyme/substrate mix (0.1 mL) was dispensed to the wells in column 12 and the plate was scanned with a fluorescent plate scanner (Perkin Elmer LS50B-excitation filter 409 nM, emission filter 530 nM).